Literature DB >> 28532993

Canine leptospirosis in Switzerland-A prospective cross-sectional study examining seroprevalence, risk factors and urinary shedding of pathogenic leptospires.

Alessandro Delaude1, Sabrina Rodriguez-Campos2, Anou Dreyfus3, Michel Jacques Counotte3, Thierry Francey1, Ariane Schweighauser1, Sophie Lettry1, Simone Schuller4.   

Abstract

Leptospirosis is an important worldwide zoonosis. While human leptospirosis remains rare in Switzerland, the incidence of canine leptospirosis is unusually high compared to other European countries. The aims of this cross-sectional study were to determine the exposure of asymtomatic dogs to pathogenic Leptospira in Switzerland, to characterise risk factors associated with seropositivity and to determine the prevalence of urinary shedding. Sampling was stratified to cover the whole of Switzerland. Sera were tested by microscopic agglutination test for antibodies against a panel of 12 serovars. Urine was tested for pathogenic Leptospira using a LipL32 real-time PCR. Of 377 sera, 55.7% (95%CI 51.2-60.7) showed a reciprocal MAT titre of ≥1:40 and 24.9% (95%CI 20.7-29.4) of ≥1:100 to at least one serovar. Seropositivity (MAT ≥1:100) was most common to serovars Australis (14.9%; 95% CI 11.4-18.6) and Bratislava (8.8%; 95%CI 6.1-11.7), followed by Copenhageni (6.1%; 95%CI 3.7-8.5), Canicola (5%; 95%CI 2.9-7.4), Grippotyphosa (4.5%; 95%CI 2.7-6.9), Pomona (4%; 95%CI 2.1-6.1), Autumnalis (2.7%; 95%CI 1.3-4.2) and Icterohaemorrhagiae (1.6%; 95%CI 0.5-2.9). In unvaccinated dogs (n=84) the prevalence of a MAT titre ≥100 was 17.9% (95%CI 10.7-26.2), with a similar distribution of reactive serovars. Variables associated with seropositivity (≥1:40) to any serovar included age (OR 1.29/year; 95%CI: 1.1-1.5) and bioregion with higher risks in the regions Northern Alps (OR 14.5; 95%CI 2.2-292.7), Central Plateau (OR 12.3; 95%CI 2.0-244.1) and Jura (OR 11.2; 95%CI 1.7-226.7) compared to Southern Central Alps. Dogs living with horses were significantly more likely to have antibodies to serovar Bratislava (OR 4.68;95%CI 1.2-17.2). Hunting was a significant risk factor for seropositivtiy to serovar Grippotyphosa (OR 8.03; 95%CI 1.6-30.8). Urine qPCR positivity was uncommon (1/408 dogs; 0.2%; 95% CI0-0.7). These results demonstrate that dogs in Switzerland are commonly exposed to pathogenic Leptospira; however, the risk of dogs contributing to the spread of Leptospira in the environment appears low.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dog; Leptospira microscopic agglutination test; Real time LipL32 PCR; Risk factors; Urinary shedding

Mesh:

Substances:

Year:  2017        PMID: 28532993     DOI: 10.1016/j.prevetmed.2017.04.008

Source DB:  PubMed          Journal:  Prev Vet Med        ISSN: 0167-5877            Impact factor:   2.670


  23 in total

1.  Pathogen-specific leptospiral proteins in urine of patients with febrile illness aids in differential diagnosis of leptospirosis from dengue.

Authors:  R Chaurasia; K C Thresiamma; C K Eapen; B J Zachariah; R Paul; M Sritharan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-13       Impact factor: 3.267

2.  Leptospira seroprevalence in owned dogs from Spain.

Authors:  M C López; A Vila; J Rodón; X Roura
Journal:  Heliyon       Date:  2019-08-27

3.  Identification of Serogroups Australis and Icterohaemorrhagiae in Two Dogs with a Severe Form of Acute Leptospirosis in Italy.

Authors:  Andrea Balboni; Silvia Zamagni; Cristina Bertasio; Maria Beatrice Boniotti; Roberta Troìa; Mara Battilani; Francesco Dondi
Journal:  Pathogens       Date:  2020-05-06

4.  Leptospiral shedding and seropositivity in shelter dogs in the Cumberland Gap Region of Southeastern Appalachia.

Authors:  Dawn Spangler; Daniel Kish; Brittney Beigel; Joey Morgan; Karen Gruszynski; Hemant Naikare; Vinayak K Nahar; Michele D Coarsey; Ashutosh Verma
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

5.  Clinical, diagnostic, and epidemiological features of a community-wide outbreak of canine leptospirosis in a low-prevalence region (Maricopa County, Arizona).

Authors:  Sally Ann Iverson; Craig Levy; Hayley D Yaglom; Heather L Venkat; Aileen Artus; Renee Galloway; Sarah Anne J Guagliardo; Laura Reynolds; Melissa JoAnne Kretschmer; Margaret E LaFerla Jenni; Peter Woodward; Alison A Reindel; Sheena Tarrant; Tammy Sylvester; Ronald Klein; Peter Mundschenk; Rebecca Sunenshine; Ilana J Schafer
Journal:  J Am Vet Med Assoc       Date:  2021-03-15       Impact factor: 1.936

6.  Urinary shedding of pathogenic Leptospira in stray dogs and cats, Algiers: A prospective study.

Authors:  Sara Zaidi; Amar Bouam; Amina Bessas; Djamila Hezil; Hicham Ghaoui; Khatima Ait-Oudhia; Michel Drancourt; Idir Bitam
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

7.  Prospective study of canine leptospirosis in shelter and stray dog populations: Identification of chronic carriers and different Leptospira species infecting dogs.

Authors:  Bruno Alonso Miotto; Aline Gil Alves Guilloux; Barbara Furlan Tozzi; Luisa Zanolli Moreno; Aline Santana da Hora; Ricardo Augusto Dias; Marcos Bryan Heinemann; Andrea Micke Moreno; Antônio Francisco de Souza Filho; Walter Lilenbaum; Mitika Kuribayashi Hagiwara
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

8.  Serological detection of anti-leptospiral antibodies in outdoor cats in Switzerland.

Authors:  Sarah Noëmi Hässle; Sabrina Rodriguez-Campos; Judith Howard; Christelle Speiser-Fontaine; Simone Schuller
Journal:  Vet Anim Sci       Date:  2019-08-27

9.  Prevalence of leptospirosis in vaccinated working dogs and humans with occupational risk

Authors:  César A Murcia; Miryam Astudillo; Marlyn H Romero
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

10.  Seroprevalence, frequency of leptospiuria, and associated risk factors in horses in Kansas, Missouri, and Nebraska from 2016-2017.

Authors:  Amanda C Trimble; Christopher A Blevins; Laurie A Beard; Ashley R Deforno; Elizabeth G Davis
Journal:  PLoS One       Date:  2018-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.